MFFIA
AZN icon

McIntyre, Freedman & Flynn Investment Advisers’s AstraZeneca AZN Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Hold
1,108
– – 0.13% 79
2026
Q1 		$219K Sell
1,108
-1
-0.1% -$193 0.12% 75
2025
Q4 		$204K Buy
+1,109
New +$195K 0.13% 74

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Aviva
Aviva London, United Kingdom $67.9B AUM 39.2% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

McIntyre, Freedman & Flynn Investment Advisers's AZN Position: Q2 2026 in Review

McIntyre, Freedman & Flynn Investment Advisers held its AstraZeneca (AZN) position steady in Q2 2026 at 1,108 shares worth $210K. The position accounts for 0.13% of the portfolio, ranked #79.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $219K in Q1 2026. 1,154 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • McIntyre, Freedman & Flynn Investment Advisers held 1,108 shares of AstraZeneca worth $210K as of Q2 2026.
  • McIntyre, Freedman & Flynn Investment Advisers left its AstraZeneca share count unchanged in Q2 2026.
  • AstraZeneca made up 0.13% of McIntyre, Freedman & Flynn Investment Advisers's portfolio in Q2 2026, its #79 holding.
  • McIntyre, Freedman & Flynn Investment Advisers first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • McIntyre, Freedman & Flynn Investment Advisers's AstraZeneca position peaked at $219K in Q1 2026.
  • 1,154 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.